Evolving consensus for immunomodulatory therapy in non-infectious uveitis during the COVID-19 pandemic.
Identifieur interne : 001298 ( Main/Corpus ); précédent : 001297; suivant : 001299Evolving consensus for immunomodulatory therapy in non-infectious uveitis during the COVID-19 pandemic.
Auteurs : Rupesh Agrawal ; Ilaria Testi ; Cecilia S. Lee ; Edmund Tsui ; Marian Blazes ; Jennifer E. Thorne ; Annabelle A. Okada ; Justine R. Smith ; Peter J. Mccluskey ; John H. Kempen ; Christoph Tappeiner ; Manisha Agarwal ; Bahram Bodaghi ; Quan Dong Nguyen ; Vishali Gupta ; Marc D. De Smet ; Manfred Zierhut ; Carlos PavesioSource :
- The British journal of ophthalmology [ 1468-2079 ] ; 2021.
English descriptors
- KwdEn :
- COVID-19 (epidemiology), Clinical Decision-Making (MeSH), Consensus (MeSH), Cross-Sectional Studies (MeSH), Glucocorticoids (therapeutic use), Humans (MeSH), Immunomodulation (MeSH), Immunosuppressive Agents (therapeutic use), Practice Guidelines as Topic (MeSH), Risk Assessment (MeSH), SARS-CoV-2 (MeSH), Surveys and Questionnaires (MeSH), Uveitis (drug therapy).
- MESH :
- chemical , therapeutic use : Glucocorticoids, Immunosuppressive Agents.
- drug therapy : Uveitis.
- epidemiology : COVID-19.
- Clinical Decision-Making, Consensus, Cross-Sectional Studies, Humans, Immunomodulation, Practice Guidelines as Topic, Risk Assessment, SARS-CoV-2, Surveys and Questionnaires.
Abstract
BACKGROUND
Immunomodulatory therapy (IMT) is often considered for systemic treatment of non-infectious uveitis (NIU). During the evolving coronavirus disease-2019 (COVID-19) pandemic, given the concerns related to IMT and the increased risk of infections, an urgent need for guidance on the management of IMT in patients with uveitis has emerged.
METHODS
A cross-sectional survey of international uveitis experts was conducted. An expert steering committee identified clinical questions on the use of IMT in patients with NIU during the COVID-19 pandemic. Using an interactive online questionnaire, guided by background experience and knowledge, 139 global uveitis experts generated consensus statements for IMT. In total, 216 statements were developed around when to initiate, continue, decrease and stop systemic and local corticosteroids, conventional immunosuppressive agents and biologics in patients with NIU. Thirty-one additional questions were added, related to general recommendations, including the use of non-steroidal anti-inflammatory drugs (NSAIDs) and hydroxychloroquine.
RESULTS
Highest consensus was achieved for not initiating IMT in patients who have suspected or confirmed COVID-19, and for using local over systemic corticosteroid therapy in patients who are at high-risk and very high-risk for severe or fatal COVID-19. While there was a consensus in starting or initiating NSAIDs for the treatment of scleritis in healthy patients, there was no consensus in starting hydroxychloroquine in any risk groups.
CONCLUSION
Consensus guidelines were proposed based on global expert opinion and practical experience to bridge the gap between clinical needs and the absence of medical evidence, to guide the treatment of patients with NIU during the COVID-19 pandemic.
DOI: 10.1136/bjophthalmol-2020-316776
PubMed: 32586933
PubMed Central: PMC7313529
Links to Exploration step
pubmed:32586933Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evolving consensus for immunomodulatory therapy in non-infectious uveitis during the COVID-19 pandemic.</title><author><name sortKey="Agrawal, Rupesh" sort="Agrawal, Rupesh" uniqKey="Agrawal R" first="Rupesh" last="Agrawal">Rupesh Agrawal</name><affiliation><nlm:affiliation>National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore rupesh_agrawal@ttsh.com.sg c.pavesio@nhs.net ndquan@stanford.edu.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Singapore Eye Research Institute, Singapore, Singapore.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>School of Material Science and Engineering, Nanyang Technological University, Singapore, Singapore.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Medical Retina and Uveitis, Moorfields Eye Hospital, NHS Foundation Trust, London, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Testi, Ilaria" sort="Testi, Ilaria" uniqKey="Testi I" first="Ilaria" last="Testi">Ilaria Testi</name><affiliation><nlm:affiliation>Department of Medical Retina and Uveitis, Moorfields Eye Hospital, NHS Foundation Trust, London, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Lee, Cecilia S" sort="Lee, Cecilia S" uniqKey="Lee C" first="Cecilia S" last="Lee">Cecilia S. Lee</name><affiliation><nlm:affiliation>Department of Ophthalmology, University of Washington, Seattle, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Tsui, Edmund" sort="Tsui, Edmund" uniqKey="Tsui E" first="Edmund" last="Tsui">Edmund Tsui</name><affiliation><nlm:affiliation>UCLA Stein Eye Institute and Department of Ophthalmology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Blazes, Marian" sort="Blazes, Marian" uniqKey="Blazes M" first="Marian" last="Blazes">Marian Blazes</name><affiliation><nlm:affiliation>Department of Ophthalmology, University of Washington, Seattle, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Thorne, Jennifer E" sort="Thorne, Jennifer E" uniqKey="Thorne J" first="Jennifer E" last="Thorne">Jennifer E. Thorne</name><affiliation><nlm:affiliation>Wilmer Eye Institute, Johns Hopkins University School of Medicine, USA, Baltimore.</nlm:affiliation></affiliation></author><author><name sortKey="Okada, Annabelle A" sort="Okada, Annabelle A" uniqKey="Okada A" first="Annabelle A" last="Okada">Annabelle A. Okada</name><affiliation><nlm:affiliation>Department of Ophthalmology, Kyorin University School of Medicine, Tokyo, New South Wales, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Smith, Justine R" sort="Smith, Justine R" uniqKey="Smith J" first="Justine R" last="Smith">Justine R. Smith</name><affiliation><nlm:affiliation>Flinders University College of Medicine and Public Health, Adelaide, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Mccluskey, Peter J" sort="Mccluskey, Peter J" uniqKey="Mccluskey P" first="Peter J" last="Mccluskey">Peter J. Mccluskey</name><affiliation><nlm:affiliation>Department of Ophthalmology, Director Save Sight Institute, The University of Sydney, Sydney, Pennsylvania, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Kempen, John H" sort="Kempen, John H" uniqKey="Kempen J" first="John H" last="Kempen">John H. Kempen</name><affiliation><nlm:affiliation>Department of Ophthalmology, Massachusetts Eye and Ear Infirmary and Harvard Medical School, Boston, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Eye Unit, MyungSung Christian Medical Center, MCM General Hospital and MyungSung Medical School, Addis Ababa, Ethiopia.</nlm:affiliation></affiliation></author><author><name sortKey="Tappeiner, Christoph" sort="Tappeiner, Christoph" uniqKey="Tappeiner C" first="Christoph" last="Tappeiner">Christoph Tappeiner</name><affiliation><nlm:affiliation>Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Agarwal, Manisha" sort="Agarwal, Manisha" uniqKey="Agarwal M" first="Manisha" last="Agarwal">Manisha Agarwal</name><affiliation><nlm:affiliation>Shroff Eye Centre, New Delhi, India.</nlm:affiliation></affiliation></author><author><name sortKey="Bodaghi, Bahram" sort="Bodaghi, Bahram" uniqKey="Bodaghi B" first="Bahram" last="Bodaghi">Bahram Bodaghi</name><affiliation><nlm:affiliation>Department of Ophthalmology,, Sorbonne University, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Nguyen, Quan Dong" sort="Nguyen, Quan Dong" uniqKey="Nguyen Q" first="Quan Dong" last="Nguyen">Quan Dong Nguyen</name><affiliation><nlm:affiliation>Byers Eye Institute, Stanford Medical School, Stanford, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Gupta, Vishali" sort="Gupta, Vishali" uniqKey="Gupta V" first="Vishali" last="Gupta">Vishali Gupta</name><affiliation><nlm:affiliation>Advanced Eye Centre, Postgraduate Institute of Medical Education (PGIMER), Chandigarh, India.</nlm:affiliation></affiliation></author><author><name sortKey="De Smet, Marc D" sort="De Smet, Marc D" uniqKey="De Smet M" first="Marc D" last="De Smet">Marc D. De Smet</name><affiliation><nlm:affiliation>Department of Ophthalmology ZNA Middelheim, Antwerp, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Zierhut, Manfred" sort="Zierhut, Manfred" uniqKey="Zierhut M" first="Manfred" last="Zierhut">Manfred Zierhut</name><affiliation><nlm:affiliation>Centre of Ophthalmology, University of Tuebingen, Tuebingen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Pavesio, Carlos" sort="Pavesio, Carlos" uniqKey="Pavesio C" first="Carlos" last="Pavesio">Carlos Pavesio</name><affiliation><nlm:affiliation>Department of Medical Retina and Uveitis, Moorfields Eye Hospital, NHS Foundation Trust, London, United Kingdom.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:32586933</idno><idno type="pmid">32586933</idno><idno type="doi">10.1136/bjophthalmol-2020-316776</idno><idno type="pmc">PMC7313529</idno><idno type="wicri:Area/Main/Corpus">001298</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001298</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Evolving consensus for immunomodulatory therapy in non-infectious uveitis during the COVID-19 pandemic.</title><author><name sortKey="Agrawal, Rupesh" sort="Agrawal, Rupesh" uniqKey="Agrawal R" first="Rupesh" last="Agrawal">Rupesh Agrawal</name><affiliation><nlm:affiliation>National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore rupesh_agrawal@ttsh.com.sg c.pavesio@nhs.net ndquan@stanford.edu.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Singapore Eye Research Institute, Singapore, Singapore.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>School of Material Science and Engineering, Nanyang Technological University, Singapore, Singapore.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Medical Retina and Uveitis, Moorfields Eye Hospital, NHS Foundation Trust, London, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Testi, Ilaria" sort="Testi, Ilaria" uniqKey="Testi I" first="Ilaria" last="Testi">Ilaria Testi</name><affiliation><nlm:affiliation>Department of Medical Retina and Uveitis, Moorfields Eye Hospital, NHS Foundation Trust, London, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Lee, Cecilia S" sort="Lee, Cecilia S" uniqKey="Lee C" first="Cecilia S" last="Lee">Cecilia S. Lee</name><affiliation><nlm:affiliation>Department of Ophthalmology, University of Washington, Seattle, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Tsui, Edmund" sort="Tsui, Edmund" uniqKey="Tsui E" first="Edmund" last="Tsui">Edmund Tsui</name><affiliation><nlm:affiliation>UCLA Stein Eye Institute and Department of Ophthalmology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Blazes, Marian" sort="Blazes, Marian" uniqKey="Blazes M" first="Marian" last="Blazes">Marian Blazes</name><affiliation><nlm:affiliation>Department of Ophthalmology, University of Washington, Seattle, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Thorne, Jennifer E" sort="Thorne, Jennifer E" uniqKey="Thorne J" first="Jennifer E" last="Thorne">Jennifer E. Thorne</name><affiliation><nlm:affiliation>Wilmer Eye Institute, Johns Hopkins University School of Medicine, USA, Baltimore.</nlm:affiliation></affiliation></author><author><name sortKey="Okada, Annabelle A" sort="Okada, Annabelle A" uniqKey="Okada A" first="Annabelle A" last="Okada">Annabelle A. Okada</name><affiliation><nlm:affiliation>Department of Ophthalmology, Kyorin University School of Medicine, Tokyo, New South Wales, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Smith, Justine R" sort="Smith, Justine R" uniqKey="Smith J" first="Justine R" last="Smith">Justine R. Smith</name><affiliation><nlm:affiliation>Flinders University College of Medicine and Public Health, Adelaide, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Mccluskey, Peter J" sort="Mccluskey, Peter J" uniqKey="Mccluskey P" first="Peter J" last="Mccluskey">Peter J. Mccluskey</name><affiliation><nlm:affiliation>Department of Ophthalmology, Director Save Sight Institute, The University of Sydney, Sydney, Pennsylvania, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Kempen, John H" sort="Kempen, John H" uniqKey="Kempen J" first="John H" last="Kempen">John H. Kempen</name><affiliation><nlm:affiliation>Department of Ophthalmology, Massachusetts Eye and Ear Infirmary and Harvard Medical School, Boston, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Eye Unit, MyungSung Christian Medical Center, MCM General Hospital and MyungSung Medical School, Addis Ababa, Ethiopia.</nlm:affiliation></affiliation></author><author><name sortKey="Tappeiner, Christoph" sort="Tappeiner, Christoph" uniqKey="Tappeiner C" first="Christoph" last="Tappeiner">Christoph Tappeiner</name><affiliation><nlm:affiliation>Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Agarwal, Manisha" sort="Agarwal, Manisha" uniqKey="Agarwal M" first="Manisha" last="Agarwal">Manisha Agarwal</name><affiliation><nlm:affiliation>Shroff Eye Centre, New Delhi, India.</nlm:affiliation></affiliation></author><author><name sortKey="Bodaghi, Bahram" sort="Bodaghi, Bahram" uniqKey="Bodaghi B" first="Bahram" last="Bodaghi">Bahram Bodaghi</name><affiliation><nlm:affiliation>Department of Ophthalmology,, Sorbonne University, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Nguyen, Quan Dong" sort="Nguyen, Quan Dong" uniqKey="Nguyen Q" first="Quan Dong" last="Nguyen">Quan Dong Nguyen</name><affiliation><nlm:affiliation>Byers Eye Institute, Stanford Medical School, Stanford, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Gupta, Vishali" sort="Gupta, Vishali" uniqKey="Gupta V" first="Vishali" last="Gupta">Vishali Gupta</name><affiliation><nlm:affiliation>Advanced Eye Centre, Postgraduate Institute of Medical Education (PGIMER), Chandigarh, India.</nlm:affiliation></affiliation></author><author><name sortKey="De Smet, Marc D" sort="De Smet, Marc D" uniqKey="De Smet M" first="Marc D" last="De Smet">Marc D. De Smet</name><affiliation><nlm:affiliation>Department of Ophthalmology ZNA Middelheim, Antwerp, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Zierhut, Manfred" sort="Zierhut, Manfred" uniqKey="Zierhut M" first="Manfred" last="Zierhut">Manfred Zierhut</name><affiliation><nlm:affiliation>Centre of Ophthalmology, University of Tuebingen, Tuebingen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Pavesio, Carlos" sort="Pavesio, Carlos" uniqKey="Pavesio C" first="Carlos" last="Pavesio">Carlos Pavesio</name><affiliation><nlm:affiliation>Department of Medical Retina and Uveitis, Moorfields Eye Hospital, NHS Foundation Trust, London, United Kingdom.</nlm:affiliation></affiliation></author></analytic><series><title level="j">The British journal of ophthalmology</title><idno type="eISSN">1468-2079</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>COVID-19 (epidemiology)</term><term>Clinical Decision-Making (MeSH)</term><term>Consensus (MeSH)</term><term>Cross-Sectional Studies (MeSH)</term><term>Glucocorticoids (therapeutic use)</term><term>Humans (MeSH)</term><term>Immunomodulation (MeSH)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Practice Guidelines as Topic (MeSH)</term><term>Risk Assessment (MeSH)</term><term>SARS-CoV-2 (MeSH)</term><term>Surveys and Questionnaires (MeSH)</term><term>Uveitis (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Glucocorticoids</term><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Uveitis</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Decision-Making</term><term>Consensus</term><term>Cross-Sectional Studies</term><term>Humans</term><term>Immunomodulation</term><term>Practice Guidelines as Topic</term><term>Risk Assessment</term><term>SARS-CoV-2</term><term>Surveys and Questionnaires</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Immunomodulatory therapy (IMT) is often considered for systemic treatment of non-infectious uveitis (NIU). During the evolving coronavirus disease-2019 (COVID-19) pandemic, given the concerns related to IMT and the increased risk of infections, an urgent need for guidance on the management of IMT in patients with uveitis has emerged.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>A cross-sectional survey of international uveitis experts was conducted. An expert steering committee identified clinical questions on the use of IMT in patients with NIU during the COVID-19 pandemic. Using an interactive online questionnaire, guided by background experience and knowledge, 139 global uveitis experts generated consensus statements for IMT. In total, 216 statements were developed around when to initiate, continue, decrease and stop systemic and local corticosteroids, conventional immunosuppressive agents and biologics in patients with NIU. Thirty-one additional questions were added, related to general recommendations, including the use of non-steroidal anti-inflammatory drugs (NSAIDs) and hydroxychloroquine.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Highest consensus was achieved for not initiating IMT in patients who have suspected or confirmed COVID-19, and for using local over systemic corticosteroid therapy in patients who are at high-risk and very high-risk for severe or fatal COVID-19. While there was a consensus in starting or initiating NSAIDs for the treatment of scleritis in healthy patients, there was no consensus in starting hydroxychloroquine in any risk groups.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>Consensus guidelines were proposed based on global expert opinion and practical experience to bridge the gap between clinical needs and the absence of medical evidence, to guide the treatment of patients with NIU during the COVID-19 pandemic.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32586933</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-2079</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>05</Month></PubDate></JournalIssue><Title>The British journal of ophthalmology</Title><ISOAbbreviation>Br J Ophthalmol</ISOAbbreviation></Journal><ArticleTitle>Evolving consensus for immunomodulatory therapy in non-infectious uveitis during the COVID-19 pandemic.</ArticleTitle><Pagination><MedlinePgn>639-647</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/bjophthalmol-2020-316776</ELocationID><Abstract><AbstractText Label="BACKGROUND">Immunomodulatory therapy (IMT) is often considered for systemic treatment of non-infectious uveitis (NIU). During the evolving coronavirus disease-2019 (COVID-19) pandemic, given the concerns related to IMT and the increased risk of infections, an urgent need for guidance on the management of IMT in patients with uveitis has emerged.</AbstractText><AbstractText Label="METHODS">A cross-sectional survey of international uveitis experts was conducted. An expert steering committee identified clinical questions on the use of IMT in patients with NIU during the COVID-19 pandemic. Using an interactive online questionnaire, guided by background experience and knowledge, 139 global uveitis experts generated consensus statements for IMT. In total, 216 statements were developed around when to initiate, continue, decrease and stop systemic and local corticosteroids, conventional immunosuppressive agents and biologics in patients with NIU. Thirty-one additional questions were added, related to general recommendations, including the use of non-steroidal anti-inflammatory drugs (NSAIDs) and hydroxychloroquine.</AbstractText><AbstractText Label="RESULTS">Highest consensus was achieved for not initiating IMT in patients who have suspected or confirmed COVID-19, and for using local over systemic corticosteroid therapy in patients who are at high-risk and very high-risk for severe or fatal COVID-19. While there was a consensus in starting or initiating NSAIDs for the treatment of scleritis in healthy patients, there was no consensus in starting hydroxychloroquine in any risk groups.</AbstractText><AbstractText Label="CONCLUSION">Consensus guidelines were proposed based on global expert opinion and practical experience to bridge the gap between clinical needs and the absence of medical evidence, to guide the treatment of patients with NIU during the COVID-19 pandemic.</AbstractText><CopyrightInformation>© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Agrawal</LastName><ForeName>Rupesh</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-6662-5850</Identifier><AffiliationInfo><Affiliation>National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore rupesh_agrawal@ttsh.com.sg c.pavesio@nhs.net ndquan@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Singapore Eye Research Institute, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Material Science and Engineering, Nanyang Technological University, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Retina and Uveitis, Moorfields Eye Hospital, NHS Foundation Trust, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Testi</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Medical Retina and Uveitis, Moorfields Eye Hospital, NHS Foundation Trust, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Cecilia S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of Washington, Seattle, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsui</LastName><ForeName>Edmund</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>UCLA Stein Eye Institute and Department of Ophthalmology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blazes</LastName><ForeName>Marian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of Washington, Seattle, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thorne</LastName><ForeName>Jennifer E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Wilmer Eye Institute, Johns Hopkins University School of Medicine, USA, Baltimore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okada</LastName><ForeName>Annabelle A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Kyorin University School of Medicine, Tokyo, New South Wales, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Justine R</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0002-4756-5493</Identifier><AffiliationInfo><Affiliation>Flinders University College of Medicine and Public Health, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCluskey</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Director Save Sight Institute, The University of Sydney, Sydney, Pennsylvania, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kempen</LastName><ForeName>John H</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0002-2967-4792</Identifier><AffiliationInfo><Affiliation>Department of Ophthalmology, Massachusetts Eye and Ear Infirmary and Harvard Medical School, Boston, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Eye Unit, MyungSung Christian Medical Center, MCM General Hospital and MyungSung Medical School, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tappeiner</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-6907-1112</Identifier><AffiliationInfo><Affiliation>Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Manisha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Shroff Eye Centre, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bodaghi</LastName><ForeName>Bahram</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology,, Sorbonne University, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Quan Dong</ForeName><Initials>QD</Initials><AffiliationInfo><Affiliation>Byers Eye Institute, Stanford Medical School, Stanford, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Vishali</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Advanced Eye Centre, Postgraduate Institute of Medical Education (PGIMER), Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Smet</LastName><ForeName>Marc D</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0002-9217-5603</Identifier><AffiliationInfo><Affiliation>Department of Ophthalmology ZNA Middelheim, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zierhut</LastName><ForeName>Manfred</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre of Ophthalmology, University of Tuebingen, Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavesio</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Retina and Uveitis, Moorfields Eye Hospital, NHS Foundation Trust, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>COVID-19 IMT Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Ophthalmol</MedlineTA><NlmUniqueID>0421041</NlmUniqueID><ISSNLinking>0007-1161</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000066491" MajorTopicYN="N">Clinical Decision-Making</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032921" MajorTopicYN="N">Consensus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056747" MajorTopicYN="Y">Immunomodulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014605" MajorTopicYN="N">Uveitis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Choroid</Keyword><Keyword MajorTopicYN="Y">Ciliary body</Keyword><Keyword MajorTopicYN="Y">Conjunctiva</Keyword><Keyword MajorTopicYN="Y">Cornea</Keyword><Keyword MajorTopicYN="Y">Drugs</Keyword><Keyword MajorTopicYN="Y">Epidemiology</Keyword><Keyword MajorTopicYN="Y">Imaging</Keyword><Keyword MajorTopicYN="Y">Immunology</Keyword><Keyword MajorTopicYN="Y">Infection</Keyword><Keyword MajorTopicYN="Y">Inflammation</Keyword><Keyword MajorTopicYN="Y">Iris</Keyword><Keyword MajorTopicYN="Y">Macula</Keyword><Keyword MajorTopicYN="Y">Retina</Keyword><Keyword MajorTopicYN="Y">Telemedicine</Keyword><Keyword MajorTopicYN="Y">Treatment lasers</Keyword><Keyword MajorTopicYN="Y">Treatment medical</Keyword><Keyword MajorTopicYN="Y">Vitreous</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>05</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>05</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32586933</ArticleId><ArticleId IdType="pii">bjophthalmol-2020-316776</ArticleId><ArticleId IdType="doi">10.1136/bjophthalmol-2020-316776</ArticleId><ArticleId IdType="pmc">PMC7313529</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001298 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001298 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32586933
|texte= Evolving consensus for immunomodulatory therapy in non-infectious uveitis during the COVID-19 pandemic.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32586933" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |